Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$51.76 USD
-0.04 (-0.08%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $51.76 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 241 - 260 ( 338 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
UX007 Development in Glut1 DS Discontinued, Has Little Impact on Valuation
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Greenlight for Early UX007 Filing is a Surprise, Updating our Program Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initial Launch Metrics should Allay Key Concerns over Crysvita
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Crysvita Launch Underway, We Remain Positive on Long- Term Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive Label and Pricing Strengthens Commercial Outlook for Crysvita
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D